Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension

Morning Hypertension and Monitoring of Metabolism (AWB Morgenhochdruck & Stoffwechselmonitoring)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02242383

Enrollment

13248

Registered

2014-09-17

Start date

2005-01-31

Completion date

Unknown

Last updated

2014-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

To evaluate efficacy and tolerability of Micardis® / MicardisPlus® under usual daily-practice prescribing conditions with a special emphasis on controlling morning blood pressure

Interventions

DRUGTelmisartan

DRUGTelmisartan in combination with hydrochlorothiazide

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- Age ≥ 18 years, insufficiently treated hypertension

Exclusion criteria

\- Age \< 18 years

Design outcomes

Primary

Measure	Time frame
Changes in morning blood pressure (BP)	Pre-dose, up to 6 months after start of treatment
Changes in metabolic laboratory parameters	Pre-dose, up to 6 months after start of treatment
Changes in morning blood pressure in patients with or without telemonitoring (TM) of BP	Pre-dose, up to 6 months after start of treatment
Investigator assessment of efficacy in reducing morning hypertension on a 5-point rating scale	Up to 6 months after start of treatment
Investigator assessment of effects on metabolism on a 3-point rating scale	Up to 6 months after start of treatment
Investigator assessment of tolerability on a 5-point rating scale	Up to 6 months after start of treatment
Number of patients with adverse events	Up to 6 months
Changes in morning heart rate	Pre-dose, up to 6 months after start of treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026